Bright Light Therapy on Sleep Health in Lung Cancer Patients

NCT07064395 | Recruiting

• 2 other identifiers: 17849F80046
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are:

• Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients?
• Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging. Participants will:
• Receive bright light exposure or usual light exposure every day for 4 weeks
• Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests
• Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks
• Keep a daily sleep log

Conditions

Lung Cancers

Keywords

bright light; intervention; biological age; sleep; lung cancer

Outcome Measures

Primary Outcomes (2)

• Change from Baseline in sleep patterns at 4 weeks

  Changes in sleep patterns will be assessed by sleep efficiency (e.g., duration of sleep in hours), sleep quality (e.g., number of sleep disturbance), and sleep onset latency (e.g., minutes of falling asleep).

  from enrollment to the end of the intervention at 4 weeks

• Changes from baseline in the measures of biological age at 4 weeks

  Participants have a lower rate of biological aging

  From enrollment to the end of intervention at 4 weeks

Secondary Outcomes (1)

• Change from Baseline in the measure of fatigue and stress at 4 weeks

  From enrollment to the end of intervention at 4 weeks

Study Arms (2)

bright light arm

EXPERIMENTAL

Participants will receive a daily 30-minutes bright light through light visor for 4 weeks.

Other: bright light

control arm

NO INTERVENTION

Participants will not receive bright light, and keep their usual daily light exposure for 4 weeks.

Interventions

bright light OTHER

Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.

bright light arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \>=18 years of age
• Stage Ib to IIIb primary lung cancer diagnosis
• \>=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy
• ECOG performance status is 0 or 1
• Experience problematic sleep (scores of \>=8 on the Insomnia Severity Index)
• Able to understand, speak, and read English
• Sighted and mentally competent to consent

You may not qualify if:

• Pregnant women
• Have metastatic cancer
• on oxygen therapy
• Current diagnosis of seasonal affective disorder or substance abuse
• Engage in shift work or travel across \>3 time zones within 2 weeks prior to the study
• Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy
• Take prescribed sedative hypnotics or antipsychotics
• Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)
• Participants with an Insomnia Severity Index \<8
• Participants with cognitive impairment (sores of \<3 mini-cog test)

Sponsors & Collaborators

• Henry Ford Health System: lead
• Michigan State University: collaborator

Study Sites (1)

Henry Ford Health System

Detroit, Michigan, 48202, United States

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Menghua Tao, PhD

CONTACT

313-590-9408; mtao1@hfhs.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Scientist

Study Record Dates

• First Submitted: June 25, 2025
• First Posted: July 14, 2025
• Study Start: June 9, 2025
• Primary Completion: February 28, 2026
• Study Completion: February 28, 2026
• Last Updated: July 14, 2025

Record last verified: 2025-06

Locations

US (1)